Prothelial (sucralfate malate, polymerized)

No dosing information is available for this tab.

Sucralfate is administered orally. The drug should be taken on an empty stomach, 1 hour before each meal and at bedtime. Antacids may be used as needed for relief of pain but should not be taken within 30 minutes before or after sucralfate.

No dosing information is available for this tab.

No dosing information is available for this tab.

Studies in animals and healthy individuals have shown that concomitant administration of sucralfate with cimetidine, digoxin, ketoconazole, phenytoin, ranitidine, tetracycline, or theophylline results in a reduction in bioavailability of these drugs. These interactions appear to be nonsystemic in origin, apparently resulting from binding of these agents to sucralfate in the GI tract. Although subtherapeutic prothrombin times with concomitant sucralfate and warfarin administration also have been reported, initiation of sucralfate in patients maintained on warfarin therapy reportedly did not alter serum warfarin concentrations or prothrombin times in at least 2 clinical studies. Although the clinical importance of these findings has not been determined in humans, it has been suggested that sucralfate be given 2 hours before or after any of these drugs. Because of the potential of sucralfate to alter the absorption of some drugs from the GI tract, separate administration of sucralfate and other drugs should be considered during concomitant therapy when alterations in bioavailability of the other drug(s) are believed to be critical.

Concomitant sucralfate, presumably because of its aluminum content, decreases GI absorption of ciprofloxacin and norfloxacin and may result in substantial (e.g., 50% or greater) decreases in serum concentrations of the anti-infectives. Patients should be instructed not to ingest sucralfate concomitantly with, or within 2 hours of, a ciprofloxacin or norfloxacin dose.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

Moderate Interaction: Assess the risk to the patient and take action as needed.

Sucralfate/Lansoprazole

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Sucralfate may decrease the absorption of lansoprazole.(3)

CLINICAL EFFECTS: The simultaneous administration of sucralfate and lansoprazole may decrease the absorption of lansoprazole, which may result in therapeutic failures.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Lansoprazole should be taken at least 30 minutes prior to sucralfate.(1)

DISCUSSION: In a single-dose crossover study, concurrent administration of lansoprazole (30 mg) with sucralfate (1 gram) resulted in delayed absorption of lansoprazole and a 17% reduction in lansoprazole's bioavailability.(1)

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Reproduction studies in mice, rats, and rabbits using sucralfate dosages up to 50 times the usual human dosage have not revealed evidence of harm to the fetus. There are no adequate and controlled studies to date using sucralfate in pregnant women, and the drug should be used during pregnancy only when clearly needed.

Since it is not known if sucralfate is distributed into milk, the drug should be used with caution in nursing women.

No enhanced messaging available.